Golimumab (GLM) ( DrugBank: Golimumab )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	2

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02687724 (ClinicalTrials.gov)	June 2016	16/2/2016	Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis	GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Mul ...	Colitis	Drug: Golimumab (GLM)	University College Dublin	NULL	Unknown status	18 Years	N/A	All	136	Phase 4	Ireland
2	EUCTR2015-004724-62-IE (EUCTR)	22/12/2015	05/11/2015	Golimumab dose variation to achieve response in Colitis	Golimumab (GLM) dose Optimisation to Adequate Levels to Achieve Response in Colitis. (GOAL-ARC)	Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Trade Name: Simponi Product Name: Simponi INN or Proposed INN: GOLIMUMAB INN or Proposed INN: GOLIMUMAB ...	UCD	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	136	Phase 4	Ireland

First Previous1Next Last